Charles River Laboratories and PathoQuest Expand Strategic Biologics Partnership
April 09 2018 - 8:00AM
Business Wire
Charles River will provide clients access to
PathoQuest’s NGS-based testing solutions
Charles River Laboratories International, Inc. (NYSE: CRL) and
PathoQuest today announced an expansion of their strategic
partnership agreement to provide next-generation sequencing (NGS)
services to the biologics industry. As part of the expanded
partnership, Charles River intends to make a direct investment in
PathoQuest.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180409005252/en/
“Our partnership with PathoQuest is integral to our ability to
provide the most sensitive testing methods to our clients in order
to ensure the safety of biological products produced by the
biopharmaceutical industry,” said Greg Beattie, Corporate Vice
President, Global Biologics Testing Solutions at Charles River.
“PathoQuest’s NGS-based testing solution provides a comprehensive
analysis that is both rapid and reliable.”
Since 2016, Charles River has provided clients access to
PathoQuest’s NGS solution, which combines a proprietary sample
preparation method, state-of-the-art equipment, and an exclusive
curated pathogen database with a comprehensive BioIT analysis
pipeline. PathoQuest’s NGS solution is a powerful test for
identifying adventitious agents in a single, comprehensive analysis
that minimizes false negatives while also providing a tool for the
genetic characterization of cell lines.
“Industry guidelines increasingly identify High-Throughput
Sequencing, also known as NGS, as a highly sensitive and reliable
testing solution,” said Jean-François Brepson, President and CEO of
PathoQuest. “We anticipate Charles River’s global footprint and
biologics-industry leadership will enable the further growth and
expansion of our platform.”
The combination of Charles River’s existing GLP and GMP
capabilities and PathoQuest’s unique offering allows for a fully
integrated, rapid, and reliable solution for the testing of
vaccines, biologics, and gene therapy products.
Caution Concerning Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of
words such as “anticipate,” “believe,” “expect,” “intend,” “will,”
“may,” “estimate,” “plan,” “outlook,” and “project,” and other
similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. Forward
looking statements include statements in this press release
regarding the growth and expansion of the NGS platform, as well as
any potential investment Charles River may make in PathoQuest.
Forward-looking statements are based on Charles River’s current
expectations and beliefs, and involve a number of risks and
uncertainties that are difficult to predict and that could cause
actual results to differ materially from those stated or implied by
the forward-looking statements. A further description of these
risks, uncertainties, and other matters can be found in the Risk
Factors detailed in Charles River's Annual Report on Form 10-K as
filed on February 13, 2018, as well as other filings we make with
the Securities and Exchange Commission. Because forward-looking
statements involve risks and uncertainties, actual results and
events may differ materially from results and events currently
expected by Charles River, and Charles River assumes no obligation
and expressly disclaims any duty to update information contained in
this news release except as required by law.
About PathoQuest
Greater Pathogen Detection for Better Decisions
PathoQuest, a spin out of Institut Pasteur, is a life sciences
company offering a game changing metagenomics approach to improving
pathogen detection in biological samples. PathoQuest’s technology
combines a Next-Generation Sequencing (NGS) platform and a
proprietary sample preparation process which is applicable to
several types of samples with a proprietary pathogen genome
sequence database and automated analysis pipeline.
Based on the company’s technological platform, PathoQuest offers
biopharmaceutical companies a disruptive approach to better
characterize and secure production of biologics. PathoQuest’s
genomic expert solution is currently being utilized by several
major biopharma companies developing vaccines, biologics and
cell/gene therapies.
PathoQuest has also developed iDTECT Blood Test, the first and
only clinical CE IVD metagenomic test in infectious disease. Using
a single blood sample, the test provides clinicians and
microbiologists with an improved method for detecting and
identifying pathogens, particularly for immunocompromised patients
with suspected infections. This new molecular diagnostic test is
designed with the objective to improve antibiotic stewardship and
lead to better patient care through precision medicine.
To learn more about PathoQuest, visit www.pathoquest.com.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180409005252/en/
Charles River Laboratories International, Inc.Investor
Contact:Susan E. Hardy, 781-222-6190Corporate Vice President,
Investor Relationssusan.hardy@crl.comorMedia Contact:Amy
Cianciaruso, 781-222-6168Corporate Vice President, Public
Relationsamy.cianciaruso@crl.comorPathoQuestChristine
Dangles, +33 (0) 170 821 790Corporate
Communicationscontact@pathoquest.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Apr 2023 to Apr 2024